# Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

> **NCT01976364** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 686 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Tofacitinib
- **DRUG:** Methotrexate
- **DRUG:** Placebo Methotrexate

## Key facts

- **NCT ID:** NCT01976364
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-17
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-05-20
- **Target enrollment:** 686 (ACTUAL)
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01976364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01976364, "Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01976364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*